Melanoma treatment showed good efficacy when administered in the early stage after the application of BRAF inhibitors (BRAFis), but drug resistance and recurrence sometimes occur when these agents are administered in a later stage, and the pathways involved in this drug resistance are diverse. The gene discussed is BRAF; the disease is melanoma.